Nanobiotix shares fall 12.5% over one week, erasing their October rebound

A decline that brings the stock back toward its 20-day moving average

Nanobiotix shares are down 2.45% at €24.70 during the session, while the SBF 120 is down 0.1%. The stock thus ranks among the largest decliners in the index.

The stock remains 3.7% above its 20-day moving average (MM20), at €23.82, but has fallen 12.5% over one week: the late-October rebound, which had pushed it above €30, has therefore clearly faded.

The 50-day moving average (MM50) at €27.89 and the 200-day moving average (MM200) at €29.27 remain well above the share price, a sign that the underlying downtrend has not been erased, with a 26.75% decline over three months.

A stock that had gained nearly 46% in one week at the end of October is thus losing part of its momentum, a pattern consistent with the high volatility observed over the past month.

Liquidity guaranteed until 2029, but a share price that remains very volatile

When it published its first-half 2026 results on September 24, Nanobiotix reported €110.9M in cash, enough to finance its operations until 2029. The company is developing NBTXR3 (JNJ-1900), a radioamplifier used in combination with radiotherapy, in partnership with Johnson & Johnson.

On October 24, the company presented to the ESMO congress the results of its melanoma cohort: a median overall survival of 17.8 months in patients resistant to anti-PD-1 therapies.

The stock is listed in Paris under the ticker NANO and on the Nasdaq as ADSs (NBTX), at a ratio of one ADS per ordinary share, and only the Paris line is eligible for the PEA. Over one year, the share still shows a gain of +38%, despite the decline over the quarter.